Evidence map›Paper›PMID 34820522›Full record

ArticleClinical mass spectrometry (Del Mar, Calif.)2020

A proposal for score assignment to characterize biological processes from mass spectral analysis of serum.

Joanna Roder, Lelia Net, Carlos Oliveira, Krista Meyer, Senait Asmellash, Sabine Kasimir-Bauer, Harvey Pass, Jeffrey Weber, Heinrich Roder, Julia Grigorieva

Open access · hybridAbstract read
In one paragraph

Article in Clinical mass spectrometry (Del Mar, Calif.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Joanna RoderBiodesix, Inc, 2970 Wilderness Place, Boulder, CO 80301, USA.
Lelia NetBiodesix, Inc, 2970 Wilderness Place, Boulder, CO 80301, USA.
Carlos OliveiraBiodesix, Inc, 2970 Wilderness Place, Boulder, CO 80301, USA.
Krista MeyerBiodesix, Inc, 2970 Wilderness Place, Boulder, CO 80301, USA.
Senait AsmellashBiodesix, Inc, 2970 Wilderness Place, Boulder, CO 80301, USA.
Sabine Kasimir-BauerDepartment of Gynecology and Obstetrics, University Hospital of Essen, Hufelandstrasse 55, 45147 Essen, Germany.
Harvey PassDepartment of Cardiothoracic Surgery, New York University Langone Medical Center, 550 1 Ave, New York, NY 10016, USA.
Jeffrey WeberPerlmutter Cancer Center at NYU Langone Medical Center, 550 1 Ave, New York, NY 10016, USA.
Heinrich RoderBiodesix, Inc, 2970 Wilderness Place, Boulder, CO 80301, USA.
Julia GrigorievaBiodesix, Inc, 2970 Wilderness Place, Boulder, CO 80301, USA.
Helix Biomedix (United States) · USNYU Langone Health · USEssen University Hospital · DE

Funding

The EDRN Mesothelioma Biomarker Discovery LaboratoryU01CA214195 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI PASS, HARVEY IRA, YANG, HAINING · 2016 to 2021
$3.5M
NCI NIH HHS U01 CA214195
6 · The paper itself

Abstract

introductionMost diseases involve a complex interplay between multiple biological processes at the cellular, tissue, organ, and systemic levels. Clinical tests and biomarkers based on the measurement of a single or few analytes may not be able to capture the complexity of a patient's disease. Novel approaches for comprehensively assessing biological processes from easily obtained samples could help in the monitoring, treatment, and understanding of many conditions.

objectivesWe propose a method of creating scores associated with specific biological processes from mass spectral analysis of serum samples.

methodsA score for a process of interest is created by: (i) identifying mass spectral features associated with the process using set enrichment analysis methods, and (ii) combining these features into a score using a principal component analysis-based approach. We investigate the creation of scores using cohorts of patients with non-small cell lung cancer, melanoma, and ovarian cancer. Since the circulating proteome is amenable to the study of immune responses, which play a critical role in cancer development and progression, we focus on functions related to the host response to disease.

resultsWe demonstrate the feasibility of generating scores, their reproducibility, and their associations with clinical outcomes. Once the scores are constructed, only 3 µL of serum is required for the assessment of multiple biological functions from the circulating proteome.

conclusionThese mass spectrometry-based scores could be useful for future multivariate biomarker or test development studies for informing treatment, disease monitoring and improving understanding of the roles of various biological functions in multiple disease settings.

Indexed as

AIR, acute inflammatory responseALK, anaplastic lymphoma kinaseANG, angiogenesisAPR, acute phase reactionBiological scoresBiomarkerBRCA1/2, Breast Cancer Gene 1, Breast Cancer Gene 2CA, complement activationCI, confidence intervalCPH, Cox proportional hazardsCV, coefficient of variationECM, extracellular matrix organizationEGFR, epidermal growth factor receptorFDA, US Food and Drug AdministrationGLY, glycolysisHbA1c, hemoglobin A1cHR, hazard ratioIFN1, interferon type 1 signaling and responseIFNg, Interferon γ signaling and responseIRn, type n immune responseIT, immune toleranceLC MS-MS, liquid chromatography with tandem mass spectrometryMALDI ToF, matrix-assisted laser desorption/ionization time of flightMass spectrometryMRM, multiple reaction monitoringMS, mass spectralm/Z, mass/chargeNSCLC, non-small cell lung cancerOS, overall survivalPCA, principal component analysisPCn, principal component nPC, principal componentPD-1, programmed cell death protein 1PD-L1, programmed death-ligand 1ProteomicsQC, quality controlSerum proteomeSet enrichment analysisWH, wound healing

Identifiers

PMID34820522
PMCPMC8601010
OpenAlexW3083795150

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.